Infectious Diseases and Your Health


Book Description

Infectious Diseases and Your Health has the potential to impact and improve your life, and the lives of your loved ones. Every day, nearly 40, 000 people including small children and women die of infectious diseases. Many of these innocent lives could be saved. Your journey through the pages of this book will take you to an amazing world of infectious diseases. You will learn about various infectious diseases, how they can affect your life, the problems associated with their treatment and prevention, and how to overcome these problems. Additionally, you will hear the success story of new drug research, be introduced to the hard facts, and find fascinating pictures of microorganisms and parasites. The book provides instant solutions to several of your concerns about infectious diseases, and you will learn to live a highly productive, long and healthy life. So, join thousands of readers of this book worldwide, enhance your life and the lives of your loving family, become an informed healthy citizen, and contribute to achieving the UN’s Sustainable Development Goals. Let us never forget: life and quality of life are very precious.




Drug Discovery and Development, Volume 1


Book Description

From first principles to real-world applications -- here is the first comprehensive guide to drug discovery and development Modern drug discovery and development require the collaborative efforts of specialists in a broadarray of scientific, technical, and business disciplines--from biochemistry to molecular biology, organic chemistry to medicinal chemistry, pharmacology to marketing. Yet surprisingly, until now, there were no authoritative references offering a complete, fully integrated picture of the process. The only comprehensive guide of its kind, this groundbreaking two-volume resource provides an overview of the entire sequence of operations involved in drug discovery and development--from initial conceptualization to commercialization to clinicians and medical practitioners. Volume 1: Drug Discovery describes all the steps in the discovery process, including conceptualizing a drug, creating a library of candidates for testing, screening candidates for in vitro and in vivo activity, conducting and analyzing the results of clinical trials, and modifying a drug as necessary. Volume 2: Drug Development delves into the nitty-gritty details of optimizing the synthetic route, drug manufacturing, outsourcing, and marketing--including drug coloring and delivery methods. Featuring contributions from a world-class team of experts, Drug Discovery and Development: * Features fascinating case studies, including the discovery and development of erythromycin analogs, Tagamet, and Ultiva (remifentanil) * Discusses the discovery of medications for bacterial infections, Parkinson's disease, psoriasis, peptic ulcers, atopic dermatitis, asthma, and cancer * Includes chapters on combinatorial chemistry, molecular biology-based drug discovery, genomics, and chemogenomics Drug Discovery and Development is an indispensable working resource for industrialchemists, biologists, biochemists, and executives who work in the pharmaceutical industry.




Covid 19 and Anthony Fauci Dossier


Book Description

World shocking evidence exposing big pharma and naming names in true crimes against humanity in preventative medicine. This vaccine patent and fraud research book free with limited edition collectible cover artwork by Stan Q. Upjohn. Dossier evidences medical crimes against humanity for financial gain of puppet masters. Dossier by Dr. Martin is fully released under a Creative Commons license CC- BY-NC-SA. For twenty years my company M-CAM has been monitoring possible violations of the 1925 Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous or other Gases and of Bacteriological Methods of Warfare (the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of Bacteriological and Toxin Weapons and Their Destruction(the BTWC). In our 2003-2004 Global Technology Assessment: Vector Weaponization M-CAM highlighted China's growing involvement in Polymerase Chain Reaction (PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Since that time, on a weekly basis, we have monitored the development of research and commercial efforts in this field, including, but not limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC), the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC), Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, many other research institutions, and their commercial affiliations. The National Institute of Health's grant AI23946-08 issued to Dr. Ralph Baric at the University ofNorth Carolina at Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci's NIAID by at least 2003) began the work on synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit. In one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments. "Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones." On April 19, 2002 - the Spring before the first SARS outbreak in Asia - Christopher M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first public record of the claims, they sought to patent a means of producing, "an infectious, replication defective, coronavirus." This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 before SARS was ever detected in humans. Against this backdrop, we noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during 2002-2003 SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Wake up and read




Medical Diagnosis


Book Description




Research and Development in the Pharmaceutical Industry (A CBO Study)


Book Description

Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...




ARISEN : Fickisms


Book Description

"Stick a dick in your ear, and fuck what you heard. Over." They were in a genuine emergency. And the men needed him panicking like they needed magic marker dicks drawn on their faces. "Hey! I'm still fuckin' this monkey. She's just here to take pictures." Ever since Master Gunnery Sergeant Fick came blitzing out of nowhere in ARISEN, Book Four - Maximum Violence, he has emerged as the closest thing to a consensus fan favorite character for the series. He is best known and most beloved for his ribald, profane, merciless, and generally hilarious insults, quips, and bon mots, which are so characteristic that readers have affectionately dubbed them: Fickisms. Now, in response to popular demand, and collected here for the first time, are all the very best tidbits of Fick's wit and wisdom, from all fourteen main series books. And thrown in as an extra special bonus, you can also enjoy the most priceless lines from both Predator, and Aliyev the Kazakh. All initial proceeds from the sale of this book will go to benefit the Marine Raider Foundation. Wit. Wisdom. And Magic Marker Dicks. FICKISMS ARISEN Fick Never Dies.




The Evolution of Drug Discovery


Book Description

Der Band zeichnet die oft spektakulären Erfolgs- oder Misserfolgsgeschichten neuartiger pharmazeutischer Wirkstoffe nach und nimmt den Leser dabei mit auf die Reise von den ersten Anfängen der Heilkunde bis zum Milliardengeschäft der modernen Pharmaindustrie. Sachkundig geschrieben, reich illustriert, anregend: Eine unterhaltsame Lektüre!




Antibiotics


Book Description

Antibiotics are truly miracle drugs. As a class, they are one of the only ones that actually cure disease as opposed to most drugs that only help relieve symptoms or control disease. Since bacteria that cause serious disease in humans are becoming more and more resistant to the antibiotics we have today, and because they will ultimately become resistant to any antibiotic that we use for treatment or for anything else, we need a steady supply of new antibiotics active against any resistant bacteria that arise. However, the antibiotics marketplace is no longer attractive for large pharmaceutical companies, the costs of development are skyrocketing because of ever more stringent requirements by the regulatory agencies, and finding new antibiotics active against resistant strains is getting harder and harder. These forces are all combining to deny us these miracle drugs when we need them the most. I provide a number of possible paths to shelter from this perfect storm.




The Flaviviruses: Detection, Diagnosis and Vaccine Development


Book Description

Over 50% of known flaviviruses have been associated with human disease. The Flavivirus genus constitutes some of the most serious human pathogens including Japanese encephalitis, dengue and yellow fever. Flaviviruses are known for their complex life cycles and epidemic spread, and are considered a globally-emergent viral threat. Detection, Diagnosis and Vaccine Development, the third volume of The Flaviviruses details the current status of technologies for detection and differentiation of these viruses, their use in surveillance and outbreak investigation, and also reviews the latest clinical research. - Comprehensive approach to the scientific disciplines needed to unravle the complexities of virus-host interactions - Descibes the technologies that have contributed to our current knowledge about the Flaviviruses - Identifies the major problems faced in understanding the virus-host interactins that result in disease - An exhaustive compendium of current and past knowledge on the Flavivirus family